Safety study to explore combination of gefitinib (ZD1839, Iressa) and radiotherapy in non-metastatic prostate cancer
Study identifier:1839IL/0118
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A phase I/II study of ZD1839 (Iressa) given concurrently with radiotherapy in patients with non-metastatic prostate cancer
Medical condition
Non-metastatic prostate cancer
Phase
Phase 1/2
Healthy volunteers
No
Study drug
Gefitinib, radiotherapy
Sex
Male
Actual Enrollment
42
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Jan 2003
Primary Completion Date: -
Study Completion Date: 01 May 2006
Study design
Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca Finland Medical Director
AstraZeneca
